Home | Contact Us | Brochure  | User Guide
0
Username
Password
Forgot Password
Capitaline Newswire App Google Play Capitaline Newswire App Store
06 Apr 2026 14:04 Sensex 73,954.30 634.75 (0.87%) || Nifty 22,918.00 204.90 (0.90%) 00
  AMC
  Single Scheme
  Multi Schemes
  Comparison
  NFO
  Charts
  MF Updates
  Miscellaneous
  Defined Sets
News
Top Equity Holdings by AMC
Interview with Fund Managers Back
30 Sep 2024 08:34
Stock Alert: Alembic Pharma, Bajel Projects, Zydus Lifesciences, Lupin, Adani Enterprises, Biocon
Stocks to watch:

Alembic Pharmaceuticals’ oral solid formulation facility (F-1) located in Panelav, Gujarat received establishment inspection report (EIR) from United States Food and Drug Administration (USFDA), which was inspected by USFDA from 17 July to 26 July 2024.

Bajel Projects had successfully entered the emerging data centre segment by securing its first order from an upcoming data centre service provider. The order involves the design and construction of a 220/33kV gas-insulated switchgear (GIS) substation and transmission line extension for a colocation data centre in Navi Mumbai, Maharashtra.

Zydus Lifesciences received final approval from the United States Food and Drug Administration (USFDA) to manufacture Enzalutamide Capsules, 40 mg.

Lupin’s Pithampur facility in Madhya Pradesh, which includes the unit-1 API and finished product manufacturing site, has completed the U.S. Food and Drug Administration (USFDA) inspection with 3 observations.

Adani Enterprises’ unit April Moon will acquire a 74% stake in Cococart Ventures for Rs 200 crore.

Adani Energy Solutions has signed a business transfer agreement with its subsidiary, North Maharashtra Power to carve out the Adani Dahanu Thermal Power Station. Adani Electricity Mumbai is a subsidiary of the company.

IndusInd Bank’s board has approved the re-apppointment of Sumant Kathpali as managing director & chief executive officer (CEO) for a term of three years, effective from 24 March 2025.This re-appointment is subject to approval by the reserve bank of India and bank’s shareholder.

Biocon’s API facility (Site 2) in Bengaluru was inspected by US Food and Drug Administration (USFDA), from 23 September to 27 September 2024 ended with four observations.

Powered by Capital Market - Live News
Other Stories
Stock Alert: D Mart, L&T ...
 (6-Apr  07:21)
Stock Alert: Hero Motocor...
 (2-Apr  07:43)
Stocks in Focus: Bharti A...
 (1-Apr  07:43)
Stock Alert: Ceigall Indi...
 (30-Mar  07:52)
Stock Alert: Infosys, HFC...
 (27-Mar  07:30)
Stock Alert: Ceigall Indi...
 (25-Mar  07:40)
Stock Alert: Coal India, ...
 (24-Mar  07:26)
Stock Alert: Union Bank o...
 (23-Mar  07:31)
Stock Alert: TCS, NTPC, N...
 (20-Mar  08:20)
Stock Alert: HDFC Bank, I...
 (19-Mar  08:10)
  FAQs  |  SEBI  |  AMFI  |  BSE  |  NSE
Glossary  |  Disclaimer   |  Privacy Policy   © Copyright 2022 All rights Reserved. Capital Market Publishers India Pvt. Ltd.